Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma

References

• Maase HVD, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–4608. doi:10.1200/JCO.2005.07.75716034041
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network: Guidelines on bladder cancer. 5 1, 2020 Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed 922, 2020.
   Google Scholar
• Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18(9):1921–1927. doi:10.1200/JCO.2000.18.9.192110784633
   PubMed Web of Science ®Google Scholar
• Maase HVD, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III Study. J Clin Oncol. 2000;18(17):3068–3077. doi:10.1200/JCO.2000.18.17.306811001674
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Wit RD, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa161368328212060
   PubMed Web of Science ®Google Scholar
• Szabados B, Dijk NV, Tang YZ, et al. Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol. 2018;73(2):149–152. doi:10.1016/j.eururo.2017.08.02228917596
   PubMed Web of Science ®Google Scholar
• Gravis G, Billon E, Baldini C, et al. Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen. Eur J Cancer. 2018;104:236–238. doi:10.1016/j.ejca.2018.09.00230316610
   PubMed Web of Science ®Google Scholar
• Beom S-H, Rha SY, Ahn JB, Shin SJ. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with advanced urothelial carcinoma. Available from: https://meetinglibrary.asco.org/record/183994/abstract. Accessed 615, 2020.
   Google Scholar
• Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification Of Tumours Of The Urinary System And Male Genital Organs-Part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.02926935559
   PubMed Web of Science ®Google Scholar
• Silva IPD, Lo S, Quek C, et al. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Cancer. 2020;126(1):86–97. doi:10.1002/cncr.3252231584722
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Schvartsman G, Peng SA, Bis G, et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2017;112:90–95. doi:10.1016/j.lungcan.2017.07.03429191606
   PubMed Web of Science ®Google Scholar
• Park SE, Lee SH, Ahn JS, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non–small cell lung cancer. J Thorac Oncol. 2018;13(1):106–111. doi:10.1016/j.jtho.2017.10.01129101058
   PubMed Web of Science ®Google Scholar
• Saleh K, Daste A, Martin N, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2019;121:123–129. doi:10.1016/j.ejca.2019.08.02631574417
   PubMed Web of Science ®Google Scholar
• Azuma T, Sugihara T, Honda S, et al. Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: a case report. Oncol Lett. 2019;17(4):4011–4015. doi:10.3892/ol.2019.1002730881514
   PubMed Web of Science ®Google Scholar
• Furubayashi N, Negishi T, Yamashita T, et al. The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. Mol Clin Oncol. 2017;7(6):1112–1118. doi:10.3892/mco.2017.145229285384
   PubMed Web of Science ®Google Scholar
• Schmid S, Diem S, Li Q, et al. Organ-specific response to nivolumab in patients with Non-Small Cell Lung Cancer (NSCLC). Cancer Immunol Immunother. 2018;67(12):1825–1832. doi:10.1007/s00262-018-2239-430171269
   PubMed Web of Science ®Google Scholar
• Lu L-C, Hsu C, Shao -Y-Y, et al. Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma. Liver Cancer. 2019;8(6):480–490. doi:10.1159/00050127531799205
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–3181. doi:10.1200/JCO.1999.17.10.317310506615
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–1855. doi:10.1200/JCO.2009.25.459920231682
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Pond GR, Fougeray R, et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013;63(4):717–723. doi:10.1016/j.eururo.2012.11.04223206856
   PubMed Web of Science ®Google Scholar
• Furubayashi N, Kuroiwa K, Tokuda N, et al. Treating Japanese patients with pembrolizumab for platinum-refractory advanced urothelial carcinoma in real-world clinical practice. J Clin Med Res. 2020;12(5):300–306. doi:10.14740/jocmr416232489505
   PubMedGoogle Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500–2501. doi:10.1056/NEJMc171344429262275
   PubMed Web of Science ®Google Scholar
• Osa A, Uenami T, Naito Y, et al. Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis. Thorac Cancer. 2019;10(11):2183–2187. doi:10.1111/1759-7714.1319731520515
   PubMed Web of Science ®Google Scholar
• Mollica V, Rizzo A, Montironi R, et al. Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma. Cancers (Basel). 2020;12(6):1449. doi:10.3390/cancers12061449
   PubMed Web of Science ®Google Scholar
• Avelumab outduels supportive care for urothelial cancer. Cancer Discov. 2020;10(7):OF4. doi: 10.1158/2159-8290.CD-NB2020-049
   Google Scholar